Menu
Search
|

Menu

Close
X

Applied Genetic Technologies Corp AGTC.OQ (NASDAQ Stock Exchange Global Market)

4.28 USD
+0.03 (+0.71%)
As of 4:00 PM EDT
chart
Previous Close 4.25
Open 4.27
Volume 17,211
3m Avg Volume 31,893
Today’s High 4.29
Today’s Low 4.07
52 Week High 7.50
52 Week Low 2.26
Shares Outstanding (mil) 18.17
Market Capitalization (mil) 77.20
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
20
FY18
24
FY17
39
FY16
47
EPS (USD)
FY19
-0.164
FY18
-1.220
FY17
-0.053
FY16
-0.107
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
41.05
Price to Sales (TTM)
vs sector
2.66
8.91
Price to Book (MRQ)
vs sector
1.02
4.65
Price to Cash Flow (TTM)
vs sector
--
28.95
Total Debt to Equity (MRQ)
vs sector
0.00
17.48
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-17.64
12.19
Return on Equity (TTM)
vs sector
-18.87
13.29

EXECUTIVE LEADERSHIP

Scott Koenig
Chairman of the Board, Since
Salary: --
Bonus: --
Susan Washer
President, Chief Executive Officer, Director, Since 2003
Salary: $464,000.00
Bonus: --
William Sullivan
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Jeffrey Chulay
Senior Vice President, Chief Medical Officer, Since 2007
Salary: $381,500.00
Bonus: --
Mark Shearman
Chief Scientific Officer, Since 2015
Salary: $350,000.00
Bonus: $50,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

14193 Nw 119Th Terrace, Suite #1
ALACHUA   FL   32615

Phone: +1386.4622204

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

SPONSORED STORIES